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The K+ channel KCNQ1 has been proposed as a tumor suppressor
in colorectal cancer (CRC). We investigated the molecular mecha-
nisms regulating KCNQ1:β-catenin bidirectional interactions and
their effects on CRC differentiation, proliferation, and invasion.
Molecular and pharmacologic approaches were used to determine
the influence of KCNQ1 expression on the Wnt/β-catenin signaling
and epithelial-to-mesenchymal transition (EMT) in human CRC cell
lines of varying stages of differentiation. The expression of KCNQ1
was lost with increasing mesenchymal phenotype in poorly differ-
entiated CRC cell lines as a consequence of repression of the
KCNQ1 promoter by β-catenin:T-cell factor (TCF)-4. In well-
differentiated epithelial CRC cell lines, KCNQ1 was localized to
the plasma membrane in a complex with β-catenin and E-cadherin.
The colocalization of KCNQ1 with adherens junction proteins was
lost with increasing EMT phenotype. ShRNA knock-down of
KCNQ1 caused a relocalization of β-catenin from the plasma mem-
brane and a loss of epithelial phenotype in CRC spheroids. Over-
expression of KCNQ1 trapped β-catenin at the plasma membrane,
induced a patent lumen in CRC spheroids, and slowed CRC cell
invasion. The KCNQ1 ion channel inhibitor chromanol 293B caused
membrane depolarization, redistribution of β-catenin into the cy-
tosol, and a reduced transepithelial electrical resistance, and stim-
ulated CRC cell proliferation. Analysis of human primary CRC
tumor patient databases showed a positive correlation between
KCNQ1:KCNE3 channel complex expression and disease-free sur-
vival. We conclude that the KCNQ1 ion channel is a target gene
and regulator of the Wnt/β-catenin pathway, and its repression
leads to CRC cell proliferation, EMT, and tumorigenesis.
KCNQ1 | β-catenin | colon cancer | epithelial–mesenchymal transition |
adherens junctions
The development of colorectal cancer (CRC) is determined bymultiple factors including ion transport (1, 2). During the last
10 years, evidence for the role of K+ channels in the develop-
ment and growth of tumors has greatly expanded. Voltage-gated
K+ channels (Kv) are involved in the proliferation of many cell
types, including intestinal cells. Although the recent literature
clearly demonstrates that Kv channels are among the targets of
interest in the fight against cancer (3–5), the specific role of each
Kv channel in tumorigenesis and the molecular mechanisms in-
volved are unknown. This is notably the case of the KCNQ1 K+
channel. The KCNQ1 gene has recently been identified as a tumor
suppressor in mouse and human CRC tissues (6). KCNQ1 de-
ficiency in mice caused rectal adenomatous hyperplasia and pro-
gression to adenocarcinoma. A loss of imprinting of KCNQ1 has
been described in CRC (7). However, the functional and molec-
ular events linking KCNQ1 and CRC progression remain unclear.
One obvious pathway, which may interact with KCNQ1, is Wnt/
β-catenin signaling, which plays a key role in driving early em-
bryogenesis, as well as intestinal homeostasis and stem cell re-
newal in the intestinal mucosa epithelia (8). Deregulation of the
β-catenin signaling axis is present in more than 80% of CRCs. This
can lead to β-catenin accumulation in the cytosol, increased nuclear
translocation of activated β-catenin, interactions with members of the
T-cell factor (TCF) family, and stimulation of β-catenin-dependent
gene expression, leading to increased cell proliferation and growth
(9). In CRC cells, excessive nuclear accumulation of β-catenin was
shown to increase the transcription of KCNQ1OT1 (10), a long
noncoding RNA known to negatively regulate KCNQ1 expression. A
possible link between β-catenin and ion channels in CRC has never
been established. In this study, we demonstrate a bidirectional in-
teraction between KCNQ1 and β-catenin regulating CRC cell dif-
ferentiation processes. We also demonstrate that KCNQ1 is a target
gene of β-catenin:TCF4, and that the expression, as well as the ion
channel function, of KCNQ1 modulate epithelial phenotype. More-
over, KCNQ1 expression and its regulatory channel subunit KCNE3
(11) were correlated with better CRC patient survival.
Results
Loss of KCNQ1 Is Associated With Mesenchymal Phenotype in CRC
Cells. In normal colonic epithelium, KCNQ1 drives Cl− secre-
tion and generates the resting membrane potential (12, 13). Low
expression of KCNQ1 has been correlated with CRC develop-
ment in APC mouse models, but the function of the channels
remains unknown (6). Using Western blotting, we compared
the expression of KCNQ1 protein in six CRC cell lines of
varying differentiation states and observed a high expression in
Significance
The K+ channel KCNQ1 has been proposed as a tumor sup-
pressor in colorectal cancer (CRC), but nothing is known about
its regulatory role in early disease stages. KCNQ1 is a target
gene of Wnt/β-catenin, which is tonically activated in CRC. We
demonstrate a bidirectional interaction between KCNQ1 and
β-catenin as a key regulator of CRC cell differentiation, pro-
liferation, and invasion. KCNQ1 stabilizes β-catenin at adherent
junctions to maintain an epithelial phenotype. The β-catenin:
T-cell factor (TCF)-4 transcriptional pathway directly represses
KCNQ1 expression, and the loss of KCNQ1 was associated with
an epithelial–mesenchymal transition. The KCNQ1:KCNE3 ion
channel complex expression in primary tumors was correlated
with good survival outcome for patients with CRC. KCNQ1 is a
potential early prognostic biomarker for CRC.
Author contributions: R.R.-M., V.B., W.T., J.M., O.S., and B.J.H. designed research; R.R.-M.,
V.B., H.H., N.L., S.F.M., B.P., F.B., and O.S. performed research; R.R.-M., V.B., H.H., N.L., S.F.M.,
B.P., F.B., O.S., and B.J.H. analyzed data; and R.R.-M., V.B., J.M., O.S., and B.J.H. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
Freely available online through the PNAS open access option.
1R.R.-M. and V.B. contributed equally to this work.
2O.S. and B.J.H. contributed equally to this work.
3To whom correspondence should be addressed. Email: bjpharvey@rcsi.ie.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1702913114/-/DCSupplemental.
www.pnas.org/cgi/doi/10.1073/pnas.1702913114 PNAS Early Edition | 1 of 6
CE
LL
BI
O
LO
G
Y
well-differentiated cells (HT29cl.19A and HT29) and a low ex-
pression in moderate to poorly differentiated cells (DLD-1,
HCT116, SW480, SW620) (Fig. 1A). This observation was con-
firmed by quantitative PCR showing a decreasing expression of
KCNQ1 mRNA with increasing mesenchymal phenotype (Fig.
1B). A high KCNQ1 expression was associated with strong ex-
pression of the epithelial marker E-cadherin and low expression
of the mesenchymal marker N-cadherin. The converse was also
found: a low expression of KCNQ1 was associated with a low
expression of E-cadherin and a high expression of N-cadherin
(Fig. 1A). Thus, it appears that KCNQ1 expression decreases with
epithelial-to-mesenchymal transition in CRC cells. The subcellular
localization of KCNQ1 was investigated using confocal immu-
nofluorescence microscopy both in CRC cells of varying
epithelial-to-mesenchymal transition (EMT) differentiation
and in isolated rat colonic crypts. In the well-differentiated
HT29cl.19A cells, as well as in rat crypt cells, the expression
of KCNQ1 was colocalized with β-catenin at the plasma
membrane (Fig. 1 C and D). In contrast, KCNQ1 was un-
detectable in the mesenchymal phenotypic SW480 cells, which
showed high abundance of β-catenin in the cytosol (Fig. 1C).
The colocalization between KCNQ1 and β-catenin was con-
firmed by van Steensel’s analysis (14) in both HT29cl.19A cells
and crypt cells in which a similar Pearson’s coefficient value was
found (SI Appendix, Fig. S1 A and B).
Activation of β-Catenin Causes Direct Transcriptional Repression of
KCNQ1. We investigated the role of β-catenin in KCNQ1 ex-
pression, using a pharmacologic approach. β-catenin activity was
increased using two inhibitors of glycogen synthase kinase 3β
(GSK3β): AR-A014418 (AR-A) and GSK3-inhibitor X (GSK3-
iX). The activation of β-catenin and its translocation into the
nuclear fraction after inhibition of GSK3β was verified in
HT29cl.19A cells (SI Appendix, Fig. S2). Activation of β-catenin
reduced KCNQ1 total abundance in HT29cl.19A cells by 60%
(Fig. 2A) and reduced the colocalization of KCNQ1 with β-catenin
at the plasma membrane (SI Appendix, Fig. S3). Similar effects of
pharmacologic agents were observed in HT29 cells (SI Appendix,
Fig. S4). In addition to the pharmacologic approach, we also used
a plasmid expressing a truncated form of β-catenin (β-catΔN87)
to constitutively activate β-catenin. HT29cl.19A and HT29 cells
transfected with activated β-catenin showed a loss of KCNQ1 and
a redistribution of β-catenin from the plasma membrane into the
cytosol (SI Appendix, Fig. S5). Chromatin immunoprecipitation
(ChIP) and luciferase assays were performed to determine the
effects of β-catenin activation on KCNQ1 transcription. We chose
SW480 cells because of their high constitutive expression of
β-catenin. Treatment with GSK3-iX to increase β-catenin activa-
tion resulted in enhanced recruitment of β-catenin and TCF4
proteins to the KCNQ1 promoter (Fig. 2 B and C). Furthermore,
the luciferase assay showed that the KCNQ1 reporter transcrip-
tional response was reduced in CHO cells treated with GSK3-iX
compared with vehicle-treated control (Fig. 2D). To confirm the
role of TCF4 in the control of KCNQ1 expression, DLD-1 and
SW480 cells, which show low constitutive KCNQ1 expression,
were transfected with a plasmid carrying a dominant negative
mutant of TCF4 (hΔNTCF4), which cannot form a complex
with β-catenin. This experiment revealed that the expression of
KCNQ1 was restored in the presence of hΔNTCF4 in both cell
lines (Fig. 2 E and F). Taken together, these data provide a
molecular mechanism by which the activated Wnt/β-catenin
pathway inhibits KCNQ1 protein expression via direct binding of
a repressive β-catenin:TCF4 complex at the KCNQ1 promoter.
KCNQ1 Modulates β-Catenin Interactions at Adherens Junctions. In
situ proximity ligation assay (PLA) revealed that KCNQ1 binds
to both E-cadherin and β-catenin, which are markers of adherens
junctions (AJ). In rat colonic crypts, KCNQ1 and β-catenin were
observed by PLA to be in close association (Fig. 3A and SI Ap-
pendix, Fig. S6). PLA dots were mainly observed at cell-to-cell
contacts, and this was verified in HT29cl.19A cells, showing that
KCNQ1 is a component of AJ in close contact (<40 nm) with
β-catenin and E-cadherin (Fig. 3B and SI Appendix, Fig. S6).
Fig. 1. KCNQ1:β-catenin interactions and EMT phenotype. (A) Western
blotting analysis of KCNQ1, E- cadherin, and N-cadherin protein expression
in a panel of CRC cell lines of varying EMT differentiation state. β-actin was
used as a loading control; images are representative of three experiments.
(B) Quantitative expression of KCNQ1 mRNA determined by qPCR showing
KCNQ1 expression in CRC cells. Data were normalized to GAPDH (n = 3).
(C) Subcellular distribution of KCNQ1 (green) and β-catenin (red) imaged by
confocal immunofluorescence microscopy. (Scale bars, 10 μm.) n = 3 in CRC
cells. (D) In isolated rat colonic crypts, n = 20 crypts form 5 rats (F-actin
in magenta). Merge images indicate colocalization between KCNQ1 and
β-catenin staining (yellow).
Fig. 2. β-catenin:TCF4 transcriptional repression of KCNQ1. (A) Western
blot and densitometry analysis of KCNQ1 expression in HT29cl.19A cells after
treatment with two GSK3-β inhibitors AR-A014418 (AR-A 20 μM) or GSK3-
inhibitor X (GSK3-iX 5 μM) (n = 5; ***P < 0.001). (B) ChIP assay revealed the
physical interaction of β-catenin and (C) TCF4 with the KCNQ1 promoter
after pharmacologic activation of β-catenin in SW480 (n = 3; *P < 0.05).
(D) Luciferase assay showing transcriptional activity at the KCNQ1 promoter
after pharmacologic activation of β-catenin by GSK3-iX (40 nM) in trans-
fected CHO cells (n = 5; **P < 0.01). (E) Western blot and densitometry
analysis of KCNQ1 expression in DLD-1 and (F) SW480 cell lines, transfected
for 48 h with a plasmid carrying a dominant negative TCF4 (hΔN-TCF4).
C-myc-tag antibody was used to monitor hΔN-TCF4 expression. Bar graphs
show expression of KCNQ1 in empty vector (EV: pcDNA3.1) and hΔN-
TCF4 transfected cells (n = 4; **P < 0.01).
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Furthermore, silencing of KCNQ1 in HT29cl.19A cells using
ShRNA resulted in a significant disruption to E-cadherin:β-cat-
enin interactions (Fig. 3C). These observations indicate the im-
portance of KCNQ1 in maintaining AJ stability and tight junction
formation. This was further demonstrated by the reduction in
transepithelial electrical resistance (TEER) in HT29cl.19A cells in
which KCNQ1 expression had been silenced (Fig. 3D). Silencing
of KCNQ1 also resulted in a redistribution of β-catenin from the
plasma membrane to a more diffuse cytosolic location (SI Ap-
pendix, Fig. S7A). Consistent with this observation, KCNQ1 si-
lencing resulted in altered phosphorylation of β-catenin at specific
residues that determine its subcellular distribution and stability.
The level of p-S33 phosphorylation that induces the degradation
of cytosolic β-catenin (15, 16) was lower in the KCNQ1 knock-
down cell lines (Fig. 3E). In contrast, phosphorylation at residues
Y654 and S675, which favor the stabilization of cytosolic β-catenin
and its translocation into the nucleus, was significantly increased in
KCNQ1-silenced cells (Fig. 3E). These results lend strong support
for the conclusion that KCNQ1 is a pivotal regulator of β-catenin
stability and subcellular distribution. As a corollary, the data in-
dicate that KCNQ1 suppresses the Wnt/β-catenin signaling path-
way. This was indeed shown to be the case where silencing
KCNQ1 expression activated signaling intermediates of the Wnt/
β-catenin pathway, increasing the expression of p-AKT, p-GSK-3-β,
cyclin D-1, cJun, and Met (SI Appendix, Fig. S7 B and C).
KCNQ1 Expression Suppresses Mesenchymal Features in CRC Spheroids.
Knock-down of KCNQ1 induced a significant increase in mesen-
chymal markers (claudin-1, β-catenin, and N-cadherin), with a
concomitant reduction in epithelial markers (ZO-1 and E-cadherin)
(Fig. 4A). When grown on a 3D matrix, highly differentiated
CRC cells such as HT29cl.19A underwent cystogenesis and
generated spheroid structures. HT29cl.19A spheroids showed
characteristic accumulation of F-actin at the apical membrane,
β-catenin lateral staining, a patent central lumen, and well-
defined adherens junctions (Fig. 4B). Knock-down of KCNQ1
significantly impaired the ability of HT29cl.19A cells to form
spheroids, and the frequency of lumen formation was reduced
from 80% to 20% (Fig. 4B).
We examined the effects of overexpression of KCNQ1 in an
intermediate EMT cell line HCT116 with low endogenous ex-
pression levels of KCNQ1. KCNQ1 construct expression in
HCT116 cells led to an increase in epithelial markers (ZO-1 and
E-cadherin) and a decrease in mesenchymal markers (β-catenin
and N-cadherin) (Fig. 5A). The overexpression of KCNQ1 in
HCT116 cells restored the ability of this moderately differenti-
ated CRC cell line to form spheroid structures, and the fre-
quency of lumen formation was increased from 19% to 62%.
(Fig. 5B). Collectively, these results demonstrate that KCNQ1 is
required to maintain a well-differentiated epithelial phenotype.
KCNQ1 Ion Channel Function and Membrane Voltage Modulate CRC
Phenotype and β-Catenin Subcellular Distribution. The function of
KCNQ1 as an ion channel is essential to maintain a hyper-
polarized negative membrane voltage in colonocytes (11, 13).
We observed that KCNQ1 overexpression in HCT116 cells in-
duced a redistribution of β-catenin and KCNQ1 at the plasma
membrane (Fig. 6A) and membrane hyperpolarization (Fig. 6B).
The membrane hyperpolarization was exclusively generated by
KCNQ1 channels, as the change in membrane potential was
inhibited by the KCNQ1 selective channel blocker chromanol
293B (Fig. 6B). The inhibition of outward K+ current flow
through KCNQ1 channels will produce a membrane depolarization.
The effects of membrane depolarization on KCNQ1 and β-catenin
Fig. 3. KCNQ1:β-Catenin and E-cadherin interactions at the plasma mem-
brane. (A) PLA showing interaction (red signal) between KCNQ1 and
β-catenin in isolated rat colonic crypts (12 crypts from 3 rats). The negative
control lacking primary antibodies is shown. Nuclear DAPI staining is in
blue. (Scale bars, 10 μm.) (B) PLA showing interaction (red signal) between
KCNQ1 and β-catenin and also between KCNQ1 and E-Cadherin in
HT29cl.19A cells. Nuclear DAPI staining is in blue (n = 3). (Scale bars, 15 μm.)
(C ) PLA showing interaction between β-catenin and E-cadherin in
HT29cl.19A stably expressing a nontargeting ShRNA (ShRD) or a ShRNA
targeting KCNQ1 mRNA (ShQ1-1). (Scale bars, 15 μm.) PLA dots quantifi-
cation is shown on the bar graph (n = 3; *P < 0.05). (D) TEER in ShRNA
KCNQ1 (ShQ1-1; ShQ1-2) HT29cl.19A monolayers (n = 6, ***P < 0.001).
Insert shows the protein expression of KCNQ1 by Western blot analysis.
(E ) Western blot and densitometry analysis of different phosphorylated
β-catenin residues in HT29cl.19A KCNQ1 knockdown cells (n = 3–5. *P <
0.05; **P < 0.01; ***P < 0.001).
Fig. 4. KCNQ1 expression and epithelial cell phenotype (A) Western blot
and densitometry analysis showing the effect of the molecular silencing of
KCNQ1 on the expression of epithelial and mesenchymal markers in
HT29cl.19A control cells (ShRD) or in HT29cl.19A ShKCNQ1 (ShQ1-1 and
ShQ1-2). Bar graph shows protein expression normalized to tubulin (n = 3–
10). *P < 0.05; **P < 0.01; ***P < 0.001. (B) Confocal immunofluorescence
images of HT29cl.19A (ShRD) and KCNQ1 knock-down cells spheroids grown
in Matrigel showing β-catenin (green), F-actin (red), nuclear staining (DAPI-
blue). (Scale bar, 20 μm.) The bar graph shows the frequency of lumen for-
mation in control ShRD and in ShKCNQ1 HT29cl.19A spheroids (n = 13–25;
P = 0.000005; Fisher’s exact test).
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cellular distribution was investigated in HT29cl.19A cells. Mem-
brane depolarization was produced by two methods: collapsing the
electrochemical gradient for K+ by exposure to high extracellular
K+ and inhibiting outward K+ currents with a specific KCNQ1 ion
channel blocker. Membrane depolarization triggered by exposing
the cells to high external K+ (predicted membrane potential from
the Nernst equation: +2 mV), caused a rapid (within 5 min) re-
distribution of KCNQ1 and β-catenin from the plasma membrane
into the cytosol (Fig. 6C). Blocking KCNQ1 channels with chro-
manol 293B (C293B) produced a similar cytosolic redistribution of
KCNQ1 and β-catenin (Fig. 6D). Transepithelial electrical re-
sistance is determined mainly by cell–cell adhesion properties of
tight junctions. Two selective blockers (C293B and HMR) of
KCNQ1 ion channels produced a decrease in ZO-1 expression and
a reduced TEER over the course of 10 d of cell culture (SI Ap-
pendix, Fig. S8). Taken together, these data demonstrate that the
function of KCNQ1 as an ion channel is essential for KCNQ1 and
β-catenin interaction and the formation of a polarized epithelium.
KCNQ1 Suppresses Proliferation and Invasion of CRC Cells.Given the
modulation of β-catenin by KCNQ1, we hypothesized that
KCNQ1 expression could modulate CRC cell proliferation.
Treatment of HT29cl.19A cells with GSK3-iX to activate β-cat-
enin and decrease KCNQ1 expression resulted in an increase in
cell proliferation (SI Appendix, Fig. S9A). Inhibition of the
KCNQ1 channel with C293B also resulted in an increase in
proliferation (SI Appendix, Fig. S9B). Conversely, increasing
KCNQ1 activity by transfection of DLD-1 cells with hΔN-
TCF4 resulted in a decrease in cell proliferation (SI Appendix,
Fig. S9C). Treatment of hΔN-TCF4 transfected DLD-1 cells
with C293B to block KCNQ1 channels rescued the proliferative
capacity (SI Appendix, Fig. S9D). Overexpression of KCNQ1 in
HCT-116 cells resulted in a decreased proliferation (SI Appen-
dix, Fig. S9E). To evaluate the role of KCNQ1 in cell invasion,
cells were subjected to a 3D Matrigel invasion assay.
HCT116 cells overexpressing the KCNQ1 construct showed a
lower rate of invasion compared with wild-type cells of low
KCNQ1 expression (SI Appendix, Fig. S10). These data dem-
onstrate that KCNQ1 channels act to repress proliferation and
invasion of CRC cells.
The KCNQ1 Channel Complex Is Associated with CRC Patient Survival.
The KCNQ1 functional channel complex in colon is composed of
the KCNQ1 pore-forming unit and a KCNE3 regulatory subunit.
In a cohort of 355 human primary colon tumor samples, Kaplan
Meier and log rank test analysis demonstrated that CRC relapse-
free survival was significantly higher for patients with high
KCNQ1 (Fig. 7A) and high KCNE3 mRNA expression (Fig. 7B).
TCF4, which we have shown to suppress the KCNQ1 promoter,
was inversely correlated with KCNQ1 expression in these pa-
tients (SI Appendix, Fig. S11). High TCF4 expression was sig-
nificantly correlated with low patient survival probability (Fig.
7C). Although KCNQ1 was correlated with patient survival, we
found no significant correlation between KCNQ1 expression and
tumor stage (SI Appendix, Table S1).
Discussion
Our study demonstrates that KCNQ1 is a target gene for the
Wnt/β-catenin pathway. We also uncovered a function of
KCNQ1 in regulating β-catenin activity at the plasma membrane.
The loss of KCNQ1 promotes the disruption of cell–cell contact,
contributing to EMT, cell proliferation, and invasion. The
function of KCNQ1 as an ion channel appears to be involved
in these processes. We describe the molecular mechanisms of
KCNQ1:β-catenin bidirectional interactions and a signaling
pathway for the tumor suppressor activity of KCNQ1 in CRC. A
number of studies have linked K+ channel deregulation to car-
cinogenesis (4, 5), but the underlying molecular mechanisms
have remained largely unknown. In this study, we demonstrate a
positive correlation between high KCNQ1 expression and CRC
cell epithelial phenotype and patient survival in primary stage
Fig. 5. Overexpression of KCNQ1 in HCT116 promotes epithelial phenotype.
(A) Western blot and densitometry analysis of epithelial and mesenchymal
protein markers in HCT116 cells transfected with a control empty vector
(HCT116) or a KCNQ1 overexpression construct (HCT116-Q1). Bar graph
shows protein expression normalized to GAPDH (n = 4; *P < 0.05; **P <
0.01). (B) Confocal immunofluorescence images of HCT116 and HCT116-
Q1 spheroids grown in Matrigel showing β-catenin (red), F-actin (magenta),
and KCNQ1 (green). (Scale bar, 20 μm.) The bar graph shows the frequency
of lumen formation in control HCT116 spheroids and in HCT116 spheroids
overexpressing KCNQ1 (n = 16; P = 0.01; Fisher’s exact test).
Fig. 6. KCNQ1 ion channel function and β-catenin membrane localization.
(A) Confocal immunofluorescence images showing the subcellular distribu-
tion of β-catenin (red) in HCT116 control cells or in HCT116 cells stably
expressing a KCNQ1 construct (HCT116-Q1). KCNQ1 is shown in green, (n =
3). (B) Membrane resting potential of HCT116 control cells and in HCT116-
Q1 cells. KCNQ1 inhibitor chromanol 293B (C293B) was used as a control (n =
6; *P < 0.05). (C) Confocal immunofluorescence images of HT29cl.19A cells
showing the subcellular distribution of β-catenin (red) and KCNQ1 (green)
after 5 min treatment with high K+ (140 mM) Krebs solution. Images are
representative of 3 independent experiments. (D) Confocal immunofluo-
rescence images of HT29cl.19A cells showing the subcellular distribution of
β-catenin (red) and KCNQ1 (green) after treatment by the specific
KCNQ1 channel blocker C293B (10 μM). Images are representative of 3 in-
dependent experiments.
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CRC. The characterization of signaling pathways regulating ion
channel expression in cancers is an open question, and very few
cases, including the overexpression of the K+ channel oncogene
EAG1 (17), have been documented so far. Here we demonstrate
that β-catenin:TCF4 signaling can regulate the expression of
KCNQ1 at the KCNQ1 promoter in CRC cells.
Wnt/β-catenin signaling represents the main pathway involved
in CRC initiation and progression (8). In this study, we showed
that differential KCNQ1 expression in CRC cell lines of varying
EMT phenotype is associated with changes in β-catenin activa-
tion and subcellular distribution. In well-differentiated CRC cell
lines, both KCNQ1 and β-catenin were colocalized at the plasma
membrane, whereas in poorly differentiated, mesenchymal
phenotype CRC cells, loss of KCNQ1 was associated with a cy-
toplasmic and nuclear redistribution of β-catenin from the
plasma membrane. These observations raise the possibility that
KCNQ1 and β-catenin coexist in a signaling complex to regulate
β-catenin subcellular localization and the development of EMT.
Activation of β-catenin using either pharmacologic inhibitors of
GSK3β or a constitutively activated β-catenin construct re-
pressed KCNQ1 expression in well-differentiated CRC cell lines,
suggesting that β-catenin translocation to the nucleus promotes
KCNQ1 repression. β-catenin is a coactivator of the transcription
factor family TCF/LEF (T-cell factor/lymphoid enhancer binding
factor), and we showed that KCNQ1 expression was repressed by
β-catenin:TCF4 binding to the KCNQ1 promoter. The key role
of TCF4 in modulating KCNQ1 expression was further sup-
ported by the finding that molecular inhibition of TCF4 activity
restored the expression of KCNQ1 in poorly differentiated CRC
cell lines. Our study provides solid evidence that KCNQ1 is a
target gene of β-catenin signaling and a regulator of the Wnt
pathway, which could explain the repression of KCNQ1 observed
in the human CRC patient cohort.
We demonstrated that KCNQ1 is associated with β-catenin
and E-cadherin at the plasma membrane in well-differentiated
CRC cell lines. The complex formed by β-catenin and E-cadherin
is constitutive proteins forming adherens junctions in epithelia
(18). Our study unveils a key role for KCNQ1 in preserving
adherens junctions and transepithelial electrical resistance
through the control of β-catenin activity and its subcellular lo-
calization. In support of such a role, we found that KCNQ1
expression influenced the β-catenin phosphorylation state. Si-
lencing of KCNQ1 decreased S33 β-catenin phosphorylation,
which enhances β-catenin stability (19). KCNQ1 knockdown in-
creased β-catenin phosphorylation at residues Tyr654 and
Ser675, which enhance β-catenin-induced transcription (20, 21).
Phosphorylation at Tyr654 reduces the β-catenin binding to
E-cadherin (22, 23), which promotes the association of β-catenin
with transcription factors in the nucleus (20). In addition,
P-Ser675 protects β-catenin from proteasomal degradation
(24, 25). These results further indicate that KCNQ1 anchors
β-catenin at the plasma membrane, stabilizing AJs and promoting
cell–cell contact. This role for KCNQ1 is supported by our
findings that KCNQ1 silencing induced a loss of spheroid or-
ganization and lumen formation in CRC 3D cultures. We
propose a model in which KCNQ1 is essential for epithelium
integrity by stabilizing AJ proteins, repressing EMT by retain-
ing β-catenin at the plasma membrane, thus limiting β-catenin:
TCF4 transcriptional activation of proliferative genes. In ad-
dition, our results suggest this function depends, in part, on the
regulation of the membrane potential by the channel. Elec-
trophysiological analyses in many cancer cell types have shown
that membrane depolarization favors cell proliferation (26).
We demonstrated that KCNQ1 maintains a hyperpolarized Vm
in CRC cells, and experimental maneuvers designed to collapse
the outward K+ currents through KCNQ1 channels disrupted
the normal KCNQ1:β-catenin interaction at the plasma mem-
brane and produced a more mesenchymal phenotype. We
conclude that the functional endpoint of the bidirectional
KCNQ1:β-catenin interaction is the regulation of proliferative
and invasive potency of CRC cells.
The loss of KCNQ1 expression is associated with poor survival
in patients with CRC liver metastases (6), and a recent study has
shown that low KCNQ1 mRNA expression correlates with poor
disease-free survival in stage II colon cancers (27). In our anal-
ysis of human primary tumors from patients with stage I to IV
disease, we observed that high expression of KCNQ1 was sig-
nificantly associated with a better patient survival outcome.
TCF4 expression showed an inverse correlation with survival
outcome in our patient cohort that is consistent with its role in
repressing KCNQ1. Intriguingly, we also found a direct correla-
tion between survival outcome and high expression of KCNE3,
the regulatory subunit of the KCNQ1 ion channel in human
colon. We also found the KCNQ1 expression, although being
significantly associated with survival, is independent of tumor
stage. This increases the attractiveness of KCNQ1:KCNE3 as a
predictive marker and a therapeutic target in CRC.
Taken together, our study demonstrates a bidirectional in-
teraction between KCNQ1 and β-catenin, which controls both
their expression and subcellular localization to modulate CRC
cell phenotype, proliferation, and invasion.
Materials and Methods
CRC Cell Culture and Spheroid Formation. HEK293T and CHO cell lines, as
well as the CRC cell lines HT29, HT29cl.19A, SW480, SW620, DLD-1, and
HCT116, were maintained in Dulbecco’s modified Eagle’s or RPMI medium
with 10% FBS. 3D-culture CRC spheroids were developed in Growth Factor
Reduced Matrigel (BD Biosciences), as further described in SI Appendix,
Materials and Methods. No human material requiring consent was used in
our experiments.
Animals and Isolation of Colonic Crypts.Male Sprague-Dawley rats (200–250 g)
were obtained from Janvier Labs and maintained at the laboratory animal
house during a short period of 24 h (local ethics committee approval was
Fig. 7. Correlation of KCNQ1:KCNE3 and TCF4 expression with CRC patient survival. Kaplan-Meier analysis of relapse-free survival from 286 colon cancer
patients. KCNQ1 (A) and KCNE3 (B) expression significantly correlated with relapse-free survival (P = 0.022; P = 0.034). Patients with high KCNQ1 and KCNE3
expression had significantly better survival rates than those with low KCNQ1 and KCNE3. (C) Low TCF4 expression significantly correlated with longer relapse-
free survival (P = 0.044).
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received from the University of Nice Sophia-Antipolis). Animals were killed
by lethal intraperitoneal injection of pentobarbital. The colon was re-
moved by dissection, and colonic crypts were isolated as previously de-
scribed in ref. 12.
Plasmid Transfection and ShRNA Transduction. Two stable KCNQ1 shRNA
knock-down cell lineswere engineered using two different DNA sequences (SI
Appendix, Materials and Methods) The double-stranded DNA sequences
were inserted in the mammalian expression vector pSuperRT Puro, a de-
rivative of the pPRIG series. Transduction experiments were performed as
previously described (28, 29). Cells were transiently transfected using
lipofectamine 2000 (Invitrogen), according to the manufacturer’s recom-
mendation. DLD-1 and SW480 cells were transfected with 2 μg hΔN-
TCF4 plasmid (30). HT29cl.19A and HT29 were transfected in suspension with
2 μg β-catΔN87 plasmid (31). KCNQ1 transduction of HTC116 cells was per-
formed as described previously (32). More details are given in SI Appendix,
Materials and Methods.
Transepithelial Electrical Resistance. HT29cl.19A cells were grown on semi-
permeable supports (Merck Millipore), and TEER was measured in triplicate
with an EVOM electrometer (WPI), using triplicates for each measurement
every 2 d for 10 d. More details are given in SI Appendix, Materials
and Methods.
Chromatin Immunoprecipitation. ChIP was carried out using a ChIP-IT High
Sensitivity Kit (Active Motif), as previously described (33). More details are
provided in SI Appendix, Materials and Methods.
Immunoblotting and Immunofluorescence. Whole-cell lysates were prepared
and subjected to 8% SDS/PAGE before proteins being transferred onto a
nitrocellulose membrane. Membranes were probed with the primary anti-
body overnight at 4 °C. Reactive proteins were developed with HRP-
conjugated secondary antibody and visualized with chemiluminescence
according to the manufacturer’s protocol (GE Healthcare). Immunostaining
was performed as previously described (12). Bound antibodies were detected
using rabbit anti IgG Alexa 488 (Invitrogen). Image acquisition was per-
formed using a Zeiss LSM710 laser scanning confocal microscope.
In situ Proximity Ligation Assay. The DuoLink PLA (Olink Bioscience) was used
to detect interactions among KCNQ1, β-catenin, and E-cadherin. HT29cl.19A
cells were seeded on poly-Lysine (40 μg/mL)-coated microscope slides. CRC
cells and isolated rat colonic crypts were fixed with paraformaldehyde 4%
and permeabilized with triton ×100 (0.05%). Cells were immunolabeled with
primary antibodies anti KCNQ1, Kv7.1 (1:100) and anti β-catenin (1:100), or
anti E-cadherin (1:100) for 1 h at 37 °C. The secondary antibodies with at-
tached PLA probes were supplied in the Duolink kit. Cellular PLA images
were captured using an inverted Zeiss Axio Observer Z1 microscope (Zeiss).
PLA dots per cells were quantified using Image J software.
Luciferase Reporter Assay. CHO cells were plated at 2 × 104 cells/well in 96-
well plates. One day after plating, the cells were washed once with PBS and
transfected with either LightSwitch GoClones KCNQ1 reporter (Active Mo-
tif), LightSwitch GAPDH Promoter Control (positive control; Active Motif), or
LightSwitch Random Promoter Control 1 (negative control) (Active Motif),
using FuGENE HD transfection reagent (Promega Corporation). After 24 h,
transfected cells were treated with 40 nM GSK3-iX (Merck Millipore) for
another 24 h. Luciferase activities were measured using the LightSwitch
Luciferase Assay Kit and LightSwitch Assay Substrate optimized for use with
RenSP luciferase, using one-step reagent addition (Active Motif).
Statistical Analysis. Mann–Whitney or Kruskal-Wallis nonparametric test
were applied to compare significance between two or more groups, as
appropriate. The frequency of lumen formation in HT29cl.19A and
HCT116 spheroids was analyzed using Fisher’s exact test. Values of n
number of experiments are given as mean ± SEM. A P value <0.05 was
considered statistically significant.
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SI Figures  and Legends  
 
 
 
Figure S1. KCNQ1 and β-catenin co-localization. (A) Van Steensel's analyses 
of KCNQ1 and β-catenin staining co-localization in HT29cl.19A cells, n= 15 from 
6 independent experiments and (B) in isolated rat colonic crypts, n= 20 from 5 
different rats. Pearson's coefficient is given by the (cross-correlation function) 
CCF value corresponding to x =0. 
 
  
Figure S2. GSK3-iX increases the expression of activated nuclear β-
catenin. (A) Western blot and densitometry analysis confirmed that treatment of 
HT29cl.19A cells with the GSK3-inhibitor X (GSK3-iX) resulted in an increased 
expression of nuclear activated β-catenin (ABC). Lamin A/C was used as loading 
control. (B) Western blot analysis confirmed that GSK3-iX treatment resulted in a 
decreased expression of cytosolic activated β-catenin (ABC). β-Actin was used 
as a loading control (n=3, ***P<0.001; ****P<0.0001). 
 
 Figure S3. GSK-3β inhibitors decrease the co-localization of KCNQ1 and β-
catenin. (A) Confocal immunofluorescence imaging of the subcellular distribution 
of KCNQ1 (green) and β-catenin (red) following activation of β-catenin with AR-
A014418 (AR-A 20µM) or GSK3-inhibitor X (GSK3-iX 5µM) in HT29cl.19A cells. 
Merged images indicate co-localization (yellow) between KCNQ1 and β-catenin 
staining. Scale bars 10 µm. n=3. (B) Van Steensel's analyses of KCNQ1 and β-
catenin staining co-localization in HT29cl.19A under control condition (black line), 
treated with AR-A (red line) or treated with GSK3-iX (blue line) n=10 from 4 
independent experiments. Pearson's coefficient is given by the CCF value 
corresponding to x=0. 
 
 
 
  
Figure S4. GSK-3β inhibitor effects on KCNQ1 and β-catenin subcellular 
localization. (A) Confocal immunofluorescence imaging of the subcellular 
distribution of KCNQ1 (green) and β-catenin (red) following activation of β-
catenin with two inhibitors of GSK-3 β; AR-A (20µM) and GSK3-iX (5µM) in HT29 
cells. The merged images indicate co-localization (yellow) of KCNQ1 with β-
catenin under control conditions. (B) Western Blot and densitometry analysis of 
KCNQ1 expression in HT29 cells following modulation of β-catenin activity. Cells 
were treated with; AR-A (20µM) or GSK3-iX (5µM) to stabilize activated β-catenin 
(n= 4; ***P< 0.001). 
  
  
Figure S5. Constitutive activation of β-catenin decreases KCNQ1 
expression and re-localizes β-catenin in CRC cells. Subcellular distribution of 
KCNQ1 (green) and β-catenin (red) following transfection (24h) of HT29 (A) and 
HT29cl.19A (B) cells with a constitutively activated mutant of β-catenin (β-
cat∆N87) or an empty vector (EV). Images are representative of 3 independent 
experiments. 
 
Figure S6. Controls for Proximity Ligation Assay. (A) PLA between KCNQ1 
and β-catenin in HEK-T cells which lack KCNQ1 expression. (B) PLA in 
HT29cl.19A without primary antibodies were used as negative controls. Nuclear 
DAPI staining is in blue (n=3). Scale bars 15µm. 
  
 
Figure S7. Silencing of KCNQ1 induces AKT phosphorylation and 
increased Wnt pathway activity. (A) Confocal immunofluorescence images 
showing subcellular localization of β-catenin (red) in HT29cl.19A ShKCNQ1 cells 
line (ShQ1-1 and ShQ1-2) or in the control HT29cl.19A ShRD cell line (n=3). 
Orthogonal views are shown on the side of merge images. Scale bars 20µm. (B) 
Western blot and densitometry analysis of KCNQ1 silencing (ShQ1-1 and ShQ1-
2) effects on AKT (S473) and GSK3-β (S9) phosphorylation in HT29cl.19A cells. 
GAPDH was used as a loading control, n=4 *** p<0.001 (C) Western blot and 
densitometry analysis of Wnt pathway target proteins expression (Cyclin D1, C-
Jun and Met) in ShRD or KCNQ1 knock-down HT29cl.19A cells (ShQ1-1 and 
ShQ1-2). Tubulin was used as a loading control, (n=4 ** p<0.01, ***p<0.001). 
 
 Figure S8. KCNQ1 regulation of transepithelial electrical resistance. 
Transepithelial electrical resistance (TEER) in HT29cl.19A epithelial monolayers, 
treated with KCNQ1 channel blockers chromanol 293B or HMR 1556 (n=6; ***P≤ 
0.001). In insert, the expression of ZO-1 protein is shown. 
 
 
Figure S9. KCNQ1 channel regulation of CRC cell proliferation (A) 
Proliferation of HT29.cl19A  cells was increased following β-Catenin activation 
24h post-treatment with GSK3-iX (40nM and 5µM). Mean ± SEM, n=6. *P<0.05, 
***P=0.003. (B) Blocking the KCNQ1 channel in HT29.cl19A cells, with the 
specific inhibitor C293B (10µM or 100µM) for 24h increased cell proliferation 
(n=3, **P<0.05). (C) Enhanced KCNQ1 expression in DLD-1 cells transfected 
with hΔN-TCF4 caused a decrease in cell proliferation measured 48h post-
transfection compared with pcDNA3.1 (Empty Vector), (n=6, ****P<0.0001). (D) 
Ion channel block of KCNQ1 in hΔN-TCF4 transfected DLD-1 cells enhanced cell 
proliferation. Cell proliferation of control (Empty Vector pcDNA3.1) and 
transfected DLD-1 cells was measured 24h post-treatment with C293B (10 µM or 
100 µM), (n=3, ****P<0.001). (E) MTS assay showing the effect of treatment with 
C293B (10µM) for 24h or ectopic expression of KCNQ1 construct (HCT116-Q1) 
on HCT 116 proliferation (n=4, *P<0.05). 
 
 
Figure S10. Over-expression of KCNQ1 channel reduces invasion of 
HCT116 cells. Representative images and quantification of Matrigel® invasion 
assays. Cells were seeded in growth-free matrigel drops and incubated at 37°C 
for 60h (bar 30µm, n=4; *p<0.05). 
 
 
 
Figure S11. Correlation between KCNQ1 and TCF4 expression in CRC 
patients. KCNQ1 mRNA expression inversely correlates with TCF4 in a cohort of 
355 colon tumour samples (data sets GSE14333 and GSE17538). Tumors were 
ordered from high to low expression of KCNQ1 (correlation coefficient, R=-0.308, 
p=3x10-9). 
  
 Table S1. Comparison between KCNQ1 expression levels and tumour 
stage.  Colon cancer data sets GSE14333 and GSE17538 were used to test for 
correlation between KCNQ1 expression and tumour stage. Two probes 
(204487_s_at, 211217_s_at) for the KCNQ1 gene were used on the Affymetrix 
Human Genome U133 Plus 2.0 microarray platform. No correlation was found 
between probe expression level and tumour stage. See Supplemental Methods 
for more details. 	
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Antibodies 
The following antibodies were purchased. Cell Signaling Technology: Phospho-β-
Catenin (Ser33/37), Phospho-β-Catenin (Ser675), Lamin A/C, Claudin-1, ZO-1. 
Sigma: KCNQ1 (SAB2108683), β–Actin (A5441), AKT, p-AKT (S473), GSK-3β, 
p-SK-3β (S9), α-Tubulin (DM1A). BD Transduction laboratories: β- catenin 
(610153), E-Cadherin, N-Cadherin. Merck Millipore: Anti-Active β- catenin (ABC) 
clone 8E7 (05-665). Thermo Scientific: c-Myc Epitope Tag Antibody (9E11). 
Santa Cruz Biotechnology: E-Cadherin (sc-8426), N-Cadherin (sc-393933), Pol II 
(sc-899), TCF4 (sc- 8631), Cyclin D1, C-Jun, MET, normal rabbit IgG (sc-2027). 
Abcam: Phospho-β-Catenin (Y654). Molecular Probe:  Phalloidin (Alexa 568). 
Dataset	 Probe	 Pearson’s	
Correlation	
Coefficient	
P-value	
GSE14333 	 	 	 	
	 204487_s_at	 0.08	 0.23	
	 211217_s_at	 -0.04	 0.56	
GSE17538	 	 	 	
	 204487_s_at	 -0.03	 0.61	
	 211217_s_at	 0.02	 0.82	
Spheroid formation 
HT29cl.19A or HCT116 cells were trypsinized to a single cell suspension of 
5×103cells/ml in 0.5% FBS completed with 2% GFR Matrigel. Cells in GFR 
Matrigel were seeded in 8-well coverglass chambers (Nalge Nunc) precoated 
with 100% GFR Matrigel (for 30min at 37°C). Cells were fed every 2 days and 
grown for 10 days. 
ShRNA transduction 
The DNA sequences of KCNQ1 ShRNA are as follow: 5’-GTA GAT CTT CCA 
GGT GGA GTT TTT TGG AAA-3’ (shQ1-1) and 5'-GAT CCC GTC TTT GCC 
ATC TCC TTC TTT GCT CGA GCA AAG AAG GAG ATG GCA AAG ATT TTT 
TGG AAA-3' (shQ1-2). 
Plasmid transduction 
cDNA coding sequence of KCNQ1 was subcloned into the modified mammalian 
expression vector pPRIG-eGFP where eGFP was exchanged for puromycin 
resistance sequence in order to generate pPriPu vector. Retroviruses were 
produced transfecting HEK 293T cells with pPriPu/KCNQ1, pCMV-VSVG, pCMV-
gag-pol plasmids, using the classic calcium phosphate transfection technique. 
Replication-defective retroviruses were recovered in the culture medium between 
48h post-transfection. This retroviral supernatant was filtered through sterile 0.45 
µm filters, then added directly to HTC 116 cells in the presence of 4 µg/ml 
polybrene to enhance retroviral transduction efficiency. 3 days later, puromycin 
was added in fresh medium to start selection of transduced cells. 
Chromatin immunoprecipitation  
Chromatin immunoprecipitation (ChIP) in SW480 cells was carried out using 
ChIP-IT® High Sensitivity Kit (Active Motif, USA) as previously described (33). 
The name and sequences of the primers, cycles and annealing temperature for 
each pair are listed in Table S2. 
Table S2. Specific primer sequences for ChIP assay 
Gene 
Symbol 
Primer 
Sequence 
Annealing 
(ºC 
             Cycles 
GAPDH (F) 5'-CCAGCAAGAGCACAAGAGGAAGAG-3' 60 40 
GAPDH (R) 5'-CAAGGGGTCTACATGGCAACTGTG-3’ 60 40 
KCNQ1 (F/R) NM_181798.1 (-)17Kb: GPH1002055(-)17A 60 40 
KCNQ1 (F/R) NM_000218.2 (-)01Kb: GPH1002054(-)01A 60 40 
 
Trans-epithelial electrical resistance 
In pharmacological experiments, HT29cl.19A cells were grown on semi-
permeable supports (Merck Millipore, 4.2cm2) and the TEER measured in 
triplicate every second day for 10 days in control conditions or treated with two 
different inhibitors of the KCNQ1 channel, Chromanol 293B (Tocris) or HMR 
1556 (Tocris). Following the 10th day of TEER measurements, the level of ZO-1 
expression was quantified by Western blot analysis. In KCNQ1 shRNA knock-
down experiments, the TEER was measured as above in HT29cl.19A Sh RD and 
HT29cl.19A ShQ1-1 and ShQ1-2 transduced cells grown on semi-permeable 
supports (Merck Millipore, 0.75cm2). Expression levels of KCNQ1 were 
determined by Western blot after 10 days of culture. 
Cell proliferation and growth assays  
Cell proliferation in vitro was measured by MTS (CellTiter 96® AQueous One 
Solution Cell Proliferation Assay, Promega Corporation). HT29, HT29cl.19A 
(1x104 cells/well), DLD-1 and HCT116 (5×103 cells/well) cells were plated in 96-
well plates in triplicate. After 24h of culture, HT29 and HT29cl.19A cells were 
treated for 24h with 40nM and 5µM of GSK3-iX (Merck Millipore) to stabilize the 
activated β-catenin or with 10µM and 100 µM of Chromanol 293B (Tocris) to 
block KCNQ1 selectively. Cell proliferation was measured 24h post-treatment 
with GSK3-iX. Cell proliferation of DLD-1 cells was measured 48h post-
transfection with pcDNA3.1 (Empty Vector) or pcDNA3.1/hΔN-TCF4. The 
absorbance was determined using a MultisKan EX Microplate ELISA Reader 
(Thermo Electron, UK) at a wavelength of 490 nm. The growth rates of cells were 
calculated using the following formula: growth rate = (1 - average value of 
untreated control well/average value of experimental well) × 100%.DLD-1 cells 
were transfected with pcDNA3.1 (Empty Vector) or pcDNA3.1/hΔN-TCF4 and 
48h post transfection were seeded at a density of 1×104 in 24-well plates and 
incubated for 5 days. Cells were then trypsinized and viability was measured 
manually by haemocytometer counting using trypan blue (Sigma) exclusion 
assay. 
Reverse transcription and quantitative real-time PCR  
Total RNA was extracted using Total RNeasy Mini Kit (Qiagen). A total of 1µg of 
RNA was reverse-transcribed into cDNA using ImProm-IITM Reverse 
Transcription System (Promega Corporation). The cDNA was subsequently used 
as a template for 40 cycles of PCR with primers specific for human KCNQ1 (or 
GAPDH which was used as a normalization control). SYBR®Green (Thermo 
Scientific) qPCR analyses were performed in triplicate on 7500 Fast Real-Time 
PCR System (Applied Biosystems). Total RNA of 3 different sets of cells was 
used to analyze gene expression. KCNQ1 mRNA expression levels were 
calculated relative to HT29cl.19A cell line. The sequences of the primers, cycles 
and annealing temperature for each pair are listed in Table S3. 
Table S3. Gene-specific primer sequences for qPCR. 
Gene 
Symbol 
Primer 
Sequence 
Annealing  
 
Cycles 
GAPDH (F) 
5'-GTCATCATCTCTGCCCCCTCTGCT-3' 
 
59 40 
GAPDH (R) 
5'-CGACGCCTGCTTCACCACCTTCT-3' 
 
58 40 
KCNQ1 (F) 
5'-GCTGAGAAAGATGCGGTGAAC-3' 
 
60 40 
KCNQ1 (R) 
5'-AGAAACAGGAGGCGATGGTCT-3' 
 
60 40 
 
Matrigel drops invasion  assay 
HCT 116 control cells and HCT116 expressing KCNQ1 (4X105 cells) were 
included in 40% growth-factor-reduced Matrigel drops and incubated in 10% FBS 
at 37°C, 5% CO2 in an incubator associated to a time laps microscope (Zeiss). 
Images were recorded every hour for 60 hours. 
Kaplan-Meier analysis 
Kaplan-Meier analysis of relapse-free patient survival in 286 primary colon 
tumors was carried out using the R2 bioinformatics web tool on previously 
published data sets GSE14333 and GSE17538 (R2: Genomics analysis and 
visualization platform (http://r2.amc.nl). Median gene expression was used to 
stratify patients into high or low expression for each gene. P-values were 
calculated based on a log rank test.  
Utilising the previously published colon cancer data sets GSE14333 and 
GSE17538 used to perform the survival analysis, we attempted to establish if 
there was a significant correlation between KCNQ1 expression and tumor stage. 
These studies used the Affymetrix Human Genome U133 Plus 2.0 microarray to 
measure the colon cancer transcriptome. There are two probes (204487_s_at, 
211217_s_at) for the KCNQ1 gene on this microarray platform. Gene expression 
values were called using the GeneChip (GC) robust multichip average method 
(1) and the data was quantile normalised using the Bioconductor package, affy 
(http://www.bioconductor.org/). For each probe, we calculated Pearson’s 
correlation coefficient between probe expression level and tumour stage. 
Van Steensel's cross correlation function 
The cross-correlation function (CCF) of a dual labeling image was calculated by 
shifting the red image over a distance ∆x pixels in the x-direction with respect to 
the green image, with −25 ≤∆x ≤25. A negative value of ∆x indicates that the red 
image was shifted to the left, a positive value indicates a shift to the right. For 
each value of ∆x Pearson’s correlation coefficient was calculated with a maximal 
value for ∆x=0. 
Electrophysiology 
Electrophysiological recordings in HCT116 or HCT116 expressing KCNQ1 cells 
were performed at room temperature in the whole cell configuration of the patch 
clamp technique. Current-clamp experiments were carried out to record the 
resting membrane potential . The bath solution was: (mM) 5 KCl, 140 NaCl, 1 
MgCl2, 1 CaCl2, and 10 Hepes (pH adjusted to 7.4 with HCl, 285mosm/l). Soft 
glass patch electrodes (Brand, Wertheim, Germany) were made on a horizontal 
pipette puller (P-97, Sutter Instrument Co., Novato, CA) to achieve a final 
resistance ranging from 3 to 5 MΩ. The pipette solution was (mM) 130 KCl, 1 
MgCl2, 1 CaCl2, 10 EGTA, 10 Hepes, 2 ATP (pH adjusted to 7.2 with KOH, 290 
mosm/l). Electrical signals were amplified with an Axopatch 200B amplifier 
(Molecular Device, Foster City, CA) and acquired with a DIGIDATA 1440 
interface and pCLAMP 10.2 software (Axon Instruments).  
Bath application of C293B (10µM) was used to selectively block KCNQ1.  
For immunofluorescence imaging using high K+ stimulation, we incubated for 5 
minutes HT29cl.19A cells grown in coverslips with control Krebs solution (in mM): 
124 NaCl, 1.5 CaCl2, 4.7 KCl, 1.2 MgSO4, 25 NaHCO3, 0.8 KH2PO4, 10 Glucose. 
In experiments in which high K+ buffer was used, a sufficient volume of K-
Gluconate was added to the standard buffer to obtain the final desired 
concentration of K+. This 100% high K+-buffer had the same composition as the 
Krebs buffer, except that 135 mM K-Gluconate was substituted for 124 mM 
NaCl/4.7 mM KCl. Both solutions were bubbled with a mixture of 5% CO2 and 
95% O2, giving a pH of 7.4.  
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